When a certificate of analysis or catalogue page arrives with typically ≥99% beside an HPLC result, the temptation is to treat the figure as a simple pass mark. For incoming-goods inspection in a UK laboratory, that is too thin a reading. The word typically describes a pattern across supplied material, not a guarantee for the vial in front of you. The number matters, but so do its scope, method, traceability and the batch document that accompanies the specific item. Research-use-only materials need a documented release check that connects the label, CoA, analytical report and storage record before anything reaches the bench.
What ‘Typically ≥99%’ Actually Represents in an Incoming-Goods File
Start by separating category-level wording from batch-level evidence. Research Sciences’ current published wording includes “≥99% Verified Purity” and “UK Research Materials Over 99.1% Purity”, while its FAQs say peptides are typically supplied at ≥99% purity by HPLC and that exact purity is stated on the CoA. Those statements are useful orientation, not a substitute for the specific CoA. A materials manager should reconfirm the live site wording and then ask for the batch certificate that applies to the delivered vial. The controlling question is not whether the shop claims ≥99%, but what this batch’s CoA states and what the accompanying chromatogram shows.
Confirm the document hierarchy first. The vial label should use the published reference format combining the SKU code and expiry date, such as BPC10-03/27, and that reference should link to the corresponding CoA. Check that the product name, catalogue code, batch or internal reference, expiry date and stated purity all align. If the CoA uses an Internal Test Reference, remember the published FAQ warning: a restocked product may carry the same ITR as earlier stock, and an ITR links to associated sample testing reports; it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. That distinction belongs in the goods-in record. Vial cap colour is not an identity, quality or manufacturing-origin indicator, so do not let packaging variation override the documents.
Also check whether the ≥99% figure is expressed as a general statement, an average, a specification or a result for the supplied batch. A phrase such as “typically ≥99%” should prompt a request for the actual result, method and chromatogram. If the CoA says purity by HPLC, confirm whether it states the method conditions and whether the result is purity by peak area. An inspector does not need to redevelop the method, but should be able to see that the claim is tied to a specific analytical record rather than copied from a category page. A headline purity figure is a reason to look deeper, not a reason to stop looking.
The Batch-Level Checks an HPLC Claim Should Trigger
Once the batch CoA is in hand, inspect the analytical story it tells. The published testing framework describes purity, identity, heavy metals and endotoxin evaluation of submitted samples, with CoAs linked to supported products. For incoming goods, confirm which of those tests are represented on the certificate for the item and which are not. The FAQs state that every compound includes a CoA for HPLC purity and identity; they also describe independent testing by HPLC and final verification and quality checks in the UK before release. Those are the shop’s stated positions and should be checked against the actual batch document, not assumed from a product title.
Read the chromatogram as well as the summary line. Confirm the reported purity is clearly linked to the chromatogram, that the integration approach is stated or at least recorded, and that the impurity profile is not hidden behind a rounded percentage. Two certificates can both say ≥99% while differing in how minor peaks are integrated, what wavelength was used, or whether the result reflects a single injection. You do not need to invent pass/fail limits beyond your laboratory’s own procedures, but you should record what the CoA actually provides. If the homepage lists “CoAs Janoshik Analytical Reports”, treat that as the shop’s published wording and open the CoA that accompanies the specific batch; do not assume that a named report applies to every vial in a restock. Identity deserves the same scrutiny: confirm that the CoA states identity testing and the method by which identity is supported, rather than relying on a retention time alone.
Contaminant screening also belongs in the inspection decision. The About page describes an expanded testing framework with heavy metals and endotoxin screening alongside CoA documentation. For a research-use-only peptide, the relevant question is whether the batch certificate records the tests that your in-vitro study and institutional risk assessment require, and whether any stated result is traceable to the submitted sample. If a test is not shown, record it as a documentation gap rather than inferring a result. The same caution applies to excipients: the FAQs state that all peptides contain trace amounts of mannitol, so confirm that the product information and CoA are consistent where excipient disclosure matters to your workflow. None of this is medical or veterinary assessment; it is controlled laboratory documentation.
Documentation, Labels and Handling Before Bench Release
Incoming-goods inspection should end with a release decision that connects paperwork to physical handling. Check that the label carries the research-use-only statement described in the FAQs: “For Research Use Only – Not for Human Consumption”, presented in line with the shop’s stated MHRA guidance position. The materials are not for human or veterinary use, and the purchaser remains responsible for lawful use, safe handling, storage, disposal and compliance with relevant UK regulations, including COSHH and laboratory safety standards. That statement should be visible in the goods-in record, because a purity figure alone does not establish suitability for a particular research application.
Confirm storage and dispatch conditions against the published guidance. Research Sciences describes temperature-aware storage and tracked UK dispatch; the handling guidance says lyophilised peptides should be stored at –20°C or below, sealed with desiccant, protected from moisture, heat and light, with repeated freeze–thaw cycles avoided. Reconstituted material is described as less stable and should be kept at 2–8°C for short-term laboratory use. If reconstitution is part of an in-vitro assay workflow, record the diluent volume and target concentration for that experiment, and remember that the shop’s free calculator and all materials are for laboratory research only, not for medical or clinical use. Any temperature excursion or damaged packaging should be documented before the vial is accepted into stock.
Finally, keep the audit trail practical. Match the delivery note, vial label, CoA, ITR and any analytical report; record the batch reference and expiry; note any documentation gap; and confirm that the product page wording matches the batch document. If a new item is being considered for a controlled in-vitro study, review the current catalogue through Buy peptides and then verify the individual product page and its batch CoA before release to the bench. That sequence keeps the ≥99% figure in its proper place: a useful prompt for inspection, not a stand-alone assurance. All items remain research-use-only and are not for human or veterinary use.
Osaka quantum-physics postdoc now freelancing from Lisbon’s azulejo-lined alleys. Kaito unpacks quantum sensing gadgets, fado lyric meanings, and Japanese streetwear economics. He breakdances at sunrise on Praça do Comércio and road-tests productivity apps without mercy.
